First treatment in 50 years for serious asthma attacks is ‘game-changer’
Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation.
Researchers say a new way of treating serious asthma and chronic obstructive pulmonary disease attacks could be a ‘game-changer’ and is the first leap in treatment for 50 years (Clive Gee/PA)
